The anti-CCL2 monoclonal antibody carlumab failed to inhibit tumor growth in early-stage clinical trials in prostate cancer as it was unable to sustain CCL2 blockade due to induction of compensatory mechanisms (258). Here, CCL2 is linked to prostate carcinoma.